WuXi Biologics (Cayman) Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
5/10
|
30.83 | 36.59 | -15.73% | 171.05 | -81.97% |
| P/S |
|
6.15 | 7.13 | -13.75% |
|
|
| P/BV |
|
2.38 | 3.66 | -34.86% |
|
|
| P/FCF |
|
387.06 | 52.22 | 641.2% |
|
|
| Ev/Ebitda |
|
26.45 | 2.91 | 809.59% |
|
|
| Ev/S |
|
9.66 | 19.3 | -49.93% |
|
|
| Ev/FCF |
|
376.51 | 60.19 | 525.54% |
|
|
| E/P |
|
0.0201 | 0.0326 | -38.38% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
9/10
|
36.51 | -9.58 | -481.35% | 37.07 | -1.49% |
| ROE |
|
9.02 | 4.42 | 104.13% |
|
|
| ROA |
|
6.41 | 2.95 | 117.23% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
19.96 | -11.15 | -279.04% |
|
|
| ROCE |
|
0 | 0.2615 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
9/10
|
0.7106 | 0.7714 | -7.88% | 0.9819 | -27.63% |
| Nеt Debt/Ebitda |
|
0 | 0.0386 | -100% |
|
|
| Debt/Ratio |
|
0.0781 | 0.1236 | -36.79% |
|
|
| Debt/Equity |
|
0.1705 | 0.7332 | -76.74% |
|
|
| Debt/Net Income |
|
1.3 | 1.65 | -21.09% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 5.7 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.13 | -100% | ||
| DSI |
|
0 | 0.5838 | -100% |
|
|
| Average dividend growth |
|
0 | 3.2 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 4.95 | -100% |
|
|
| Average percentage for payments |
|
40.57 | 24.82 | 63.49% |
|
|
| Difference from average difference in sector |
|
-5.7 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
327.6 | 1.85 | 17608.11% | ||
| Growth impulse Ebitda in 5 years |
|
555.74 | -44.43 | -1350.82% | ||
| Growth impulse Net Income in 5 years |
|
235.34 | 58.07 | 305.27% | ||
| Growth impulse FCF in 5 years |
|
-121.57 | -7.48 | 1525.27% | ||
| Growth impulse EPS in 5 years |
|
174.31 | -198.43 | -187.84% |
IP Score
5.26/10
